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content [2]. CMR has the ability to distinguish fat, fluid and 
soft tissue by using different imaging protocols that exploit 
different intrinsic tissue properties [3, 4]. The linear corre-
lation between myocardial water content and T2 transverse 
relaxation time in acute myocardial infarction was first 
described in the early 80s; T2-weighted sequences were 
subsequently developed and implemented in clinical prac-
tice to assess the presence of myocardial oedema, which 
appears as an area of increased signal intensity (bright). 
Pathophysiologic model of acute ischemia after coronary 
occlusion shows a rapid onset of myocardial oedema, 
which can be detected as early as 30 min from symptoms 
onset on T2-weighted images (Fig. 1a) [5]. The territory of 
distribution of the infarct-related artery is at risk of poten-
tially irreversible damage (myocardium at risk) if reperfu-
sion does not occur promptly [6]. When myocardial blood 
flow is promptly restored, the irreversibly damaged myo-
cardial area is significantly smaller than the area at risk. 
T2-weighted sequences can detect the presence and extent 
of the myocardium at risk and derive the amount of myo-
cardial salvage by subtracting the extent of scarred myocar-
dium in the post-contrast sequences (late gadolinium 
enhancement, LGE) (Fig.  1b) from the area at risk on 
T2-weighted images. T2-weighted sequences for the 
assessment of the area at risk have been validated in animal 
studies versus the gold standard fluorescent microspheres, 
showing comparable findings [7]. The assessment of sal-
vage myocardium is reproducible and has been validated 
against SPECT and angiographic studies [5]; moreover, 
while SPECT tracer needs to be given prior to revasculari-
zation, CMR provides the opportunity to assess salvage 
myocardium retrospectively, few days after the acute event, 
without interfering with the acute clinical management [8]. 
Identification of myocardial oedema in a patient with sus-
pected acute coronary syndrome (ACS) not only confirms 
Abstract Cardiovascular magnetic resonance (CMR) is a 
multi-parametric, multi-planar, non-invasive imaging tech-
nique, which allows accurate determination of biventricu-
lar function and precise myocardial tissue characterization 
in a one-stop-shop technique, free from the use of ionizing 
radiations. Though CMR has been increasingly applied 
over the last two decades in every-day clinical practice, its 
widest application has been in the assessment of ischemic 
cardiomyopathy.
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Acute myocardial infarction
Coronary artery disease (CAD) is the leading cause of 
death worldwide [1]. Although the incidence rate of ST-
elevation myocardial infarction (STEMI) has declined, that 
of non-ST elevation myocardial infarction (NSTEMI) has 
increased over the last few decades [1]. Diagnosis usually 
relies on clinical history and electrocardiographic changes, 
while imaging, mainly trans-thoracic echocardiography 
(TTE), is usually deferred.
Acute coronary occlusion determines cytogenic and 
vasogenic myocardial oedema, which is a rather non-spe-
cific response to an acute insult (ischemic, inflammatory, 
traumatic), and is characterized by an increase in water 
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the diagnosis, but also helps in establishing the age of the 
myocardial infarction [9]. All patients presenting with ACS 
and those with high pre-test probability of CAD undergo 
coronary angiography in keeping with existing guidelines. 
However, in a non-negligible proportion of patients with 
ACS (approximately one-third), a “culprit” lesion is not 
identified by angiogram [10]; these cases are often attrib-
uted to undetectable coronary pathology, such as distal 
embolization, coronary spasm and myocardial bridging. 
According to the ischemic wave-front phenomenon, myo-
cardial oedema extends from the subendocardium to the 
entire wall thickness of the territory supplied by the 
occluded vessel. Based on this pathophysiologic model, 
T2-weighted sequences can easily allow the detection of 
the culprit lesion, as an area of increased signal intensity 
along the distribution territory of a coronary artery 
(Fig. 1a). Monney et al. [11] found that myocardial infarc-
tion was identified in 13% of patients with ACS and unob-
structed coronaries, as delineated by a localised increase in 
signal intensity on T2-weighted images in areas of trans-
mural scar. Though persistence of myocardial oedema after 
an acute event varies according to different studies, infarct 
Fig. 1  Myocardial infarc-
tion: overview. T2-weighted 
two chamber long axis view 
showing myocardial oedema in 
the basal to mid-cavity inferior 
wall (a) with concomitant 
subendocardial late gadolinium 
enhancement (LGE) in the 
post-contrast sequence (b) in a 
patient with acute subendocar-
dial infarction in the proximal 
to mid right coronary artery 
territory. T2-weighted three 
chamber long axis view show-
ing myocardial oedema in the 
mid-apical anteroseptum with 
evidence of a hypo-intense 
core (c, white arrow), con-
sistent with intramyocardial 
haemorrhage, in a patient with 
transmural infarction in the 
distal left anterior descending 
territory (d) with persistence 
of microvascular obstruction 
(d, white arrow). Four chamber 
long axis post-contrast view 
showing subendocardial LGE 
of the mid-cavity anterolateral 
wall (e). Two chamber long 
axis post-contrast view showing 
transmural LGE of the mid-
apical inferior wall (f)
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related oedema can persist from few weeks to few months 
after the event, so that it can also be detected once cardiac 
biomarkers have normalized [5]. As the abnormalities are 
transient, imaging these patients within 2 weeks from the 
event represents an optimal time window before the abnor-
malities resolve and become no longer detectable [12]. Not 
all patients in the NSTEMI-ACS population have evidence 
of CAD requiring revascularization; Raman et  al. [13] 
showed that the presence of myocardium at risk on 
T2-weighted CMR sequences allows the identification of 
patients who will benefit from an early invasive manage-
ment. In fact, the presence of myocardial oedema has been 
shown to increase the risk of adverse cardiovascular events, 
irrespective of revascularization [14]. Clinical evidence has 
shown that prompt myocardial revascularization reduces 
the infarcted area and the incidence of long-term adverse 
events. However, myocardial revascularization can itself 
also lead to myocardial damage, the so called 
“ischemia–reperfusion injury”, as shown by histology stud-
ies soon after revascularization. Prolonged ischemia-
induced microvascular damage leads to absent distal myo-
cardial flow (no-reflow phenomenon) on coronary 
angiography, which can be identified as either microvascu-
lar obstruction or intra-myocardial haemorrhage (IMH) on 
CMR. Both entities are a consequence of microvascular 
cell necrosis and present in the context of a large and late 
reperfused myocardial infarction [15]. Cardiovascular mag-
netic resonance soon after an acute ischemic event is able 
to detect the ischemia–reperfusion injury (Fig. 1c, d). The 
imaging equivalent of the angiographic and histologic no-
reflow phenomenon is known as microvascular obstruction 
(MVO) and appears as a non-perfused, non-contrast gain-
ing area within the infarcted myocardium (Fig. 1d); this can 
be detected after contrast administration and has typically 
low signal intensity (black) both in the early and late acqui-
sition (5 and 15 min after contrast administration, respec-
tively). As contrast agent needs time to diffuse into the non-
perfused area, MVO extent also depends on time to image 
acquisition, appearing larger early after contrast adminis-
tration and smaller when the images are acquired later as 
the contrast ultimately fills in these areas [16]. Extensive 
late MVO thus represents more severe microvascular dam-
age [8]. Rochitte et al. [17] have shown that there is a time-
course of MVO development, with onset within the first 
3.5 h from the acute event, and subsequent expansion over 
the following 48 h. MVO increases up to three times during 
the first 2 days, reaching a steady-state between day 2 and 
9, that represent the best time to quantify MVO [18]. By 
reflecting extensive microvascular damage, MVO has been 
shown to provide important prognostic insights. There is a 
linear relation between MVO extent and scar size, not only 
in the acute but also in the chronic setting, as the acute 
MVO is a predictor of transmural extent at 6 months [19]. 
MVO is a powerful predictor of adverse cardiovascular out-
come, also independent of left ventricular ejection fraction 
(LVEF) [8, 19–22]. On a cohort of 438 reperfused STEMI 
patients undergoing CMR within 3 days from the acute 
event, in contrast to early MVO, only late MVO indepen-
dently predicted adverse events [23]. De Waha et  al. also 
showed that the ratio MVO/scar size is a more powerful 
predictor of adverse outcome then either considered alone 
[24]. Extravasation of erythrocytes into the myocardium as 
a consequence of disruption of capillaries and break-down 
of capillary barrier can be easily detected as a dark core 
area on T2-weighted images (Fig. 1c), due to the intrinsic 
paramagnetic properties of haemoglobin breakdown prod-
ucts, which shorten T2 relaxation time. Intramyocardial 
haemorrhage has been shown to be significantly related to 
infarct size and time to reperfusion, both in experimental 
models and in patients after percutaneous or surgical myo-
cardial revascularization [15]. Out of 346 patients undergo-
ing CMR after acute reperfused STEMI, Eitel et  al. [25] 
found evidence of IMH in 35% of patients; in a multivaria-
ble model, infarct size, MVO extent and impaired LVEF 
were the strongest predictors of IMH. As expression of 
severe reperfusion injury, IMH has proved to have prognos-
tic implications [25–27], demonstrating a strong unadjusted 
association with major adverse cardiovascular events [25, 
27]. Intramyocardial haemorrhage is also a determinant of 
adverse left ventricular remodelling at 6 months follow-up; 
each myocardial segment showing IMH on T2-weighted 
images increases the risk of dilated left ventricular end-sys-
tolic volume by 50% [27].
Complications of acute myocardial infarction
With the onset of the reperfusion era, mechanical complica-
tions of acute MI, which are associated with reduced short- 
and long-term survival, have reduced to <1% [28] (Fig. 2). 
The most encountered mechanical complications include 
ventricular free wall (Fig.  2a) or septal rupture, papil-
lary muscle infarction (Fig. 2c) or rupture with secondary 
acute mitral regurgitation (MR), ventricular aneurysm and 
pseudo-aneurysm (Fig. 2b). With its superior spatial reso-
lution and feasibility soon after the acute event, CMR is a 
promising tool for the identification of early and late MI 
complications [20]. Post MI ventricular septal defect (VSD) 
is associated with 80–90% mortality within few months 
after acute event; not only is CMR useful to make the diag-
nosis, but also tissue characterization to look for fibrosis of 
VSD edges helps identifying the most appropriate time for 
surgery [20]. Myocardial tissue characterization by CMR 
also allows to distinguish a true aneurysm, which is char-
acterised by a large neck and typically enhanced aneurysm 
wall, from pseudo-aneurysm, which usually has a small 
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neck, with non-enhanced wall, and represents a contained 
rupture [20]. A lipomatous metaplasia seen as a high sig-
nal intensity area in the cine and post-contrast sequences, 
is also commonly seen in patients with old MI who under-
went surgical myocardial revascularization [20]. The right 
ventricle (RV) is involved in a non-negligible propor-
tion of acute MI, mainly involving the inferior wall (inci-
dence 24–50%) [29], is haemodinamically relevant in up 
to 25–50% of cases and is usually associated with poorer 
prognosis [30, 31] (Fig. 2d). CMR has shown to detect RV 
involvement in 25% of patients with inferior MI, a percent-
age that is significantly superior to that detected by ECG 
and trans-thoracic echocardiogram (TTE). CMR studies 
have shown that RV myocardial infarction is usually asso-
ciated with larger MI, lower LVEF and lower RV ejection 
fraction [30, 32]. LV thrombus is a frequent complication 
of ischemic heart disease, whose incidence increases with 
poor LVEF, greater scar size and ischemic aetiology [33] 
Fig. 2  Complications of acute 
myocardial infarction. Two 
chamber long axis post-contrast 
sequence showing contained 
chronic rupture of the ante-
rior wall (a, white arrow) 
in a patient with transmural 
myocardial infarction in the 
left anterior descending ter-
ritory. Three chamber long 
axis cine sequence showing 
large pseudo-aneurysm of the 
mid-cavity inferolateral wall 
(b) with evidence of flow (b, 
white arrow-head) between a 
“tunnel-like” connection with 
the left ventricle in a patient 
with trasmural infarction in the 
left circumflex territory. Mid-
cavity short-axis post-contrast 
sequence showing myocardial 
infarction of the papillary mus-
cles (c). Mid-cavity short-axis 
post-contrast sequence showing 
myocardial infarction of the 
right ventricular inferior wall 
(d, black arrow) in a patient 
with transmural infarction in 
the basal inferior wall. Early (e) 
and late (f) four chamber long 
axis gadolinium enhancement 
sequences showing a large api-
cal thrombus in a patient with 
transmural myocardial infarc-
tion in the distal left anterior 
descending territory (f)
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and whose diagnosis once relied on TTE. Given thrombus 
is avascular, it typically appears as a non-contrast gaining 
structure early (Fig. 2e) and late (Fig. 2f) after gadolinium 
administration on CMR; detection of thrombus by CMR 
has shown to be superior to TTE [34], also after contrast 
administration [35].
Acute coronary syndromes with normal 
angiogram
Up to a third of patients presenting with ACS shows nor-
mal arteries on coronary angiogram [12], making diagnosis 
and management challenging. Identifying a final diagnosis 
is important to guide patients’ management as it has impli-
cations both on medical therapy (secondary prevention if it 
was a confirmed ACS) and prognosis [12]. A recent meta-
analysis on patients with myocardial infarction and unob-
structed coronaries reported in-hospital and 12 months all-
cause mortality of 0.9 and 4.7%, respectively [36]. Among 
the differentials, the commonest causes of ACS with nor-
mal angiogram are acute myocarditis, MI secondary to dis-
tal embolization, coronary spasm or spontaneous recanali-
zation and Tako-Tsubo cardiomyopathy (TTC). CMR plays 
a pivotal role in the diagnosis of these entities, mainly based 
on its higher spatial resolution and superior tissue charac-
terization properties [37, 38]. The unique selling point of 
CMR is indeed its ability to characterize myocardial tis-
sue, based on the typical distribution pattern of the contrast 
agent, gadolinium: ischemic cardiomyopathy, following 
the ischemic wave-front, is typically characterized by late 
gadolinium enhancement (LGE) with a subendocardial to 
transmural distribution, while non-ischemic cardiomyopa-
thy shows LGE with a mid-wall or epicardial distribution 
pattern, generally not located in the territory of distribution 
of a coronary artery [39]. A meta-analysis on more than 
500 patients presenting with MI and unobstructed coronar-
ies showed that one-third of patients had findings consistent 
with myocarditis [40] (Fig.  3a, b). Epicardial or mid-wall 
increased signal intensity on T2-weighted and early gado-
linium enhancement sequences (Fig.  3a), with additional 
LGE in the post-contrast sequences (Fig. 3b), are the typi-
cal findings of acute myocarditis on CMR, which accurately 
resemble histologic Lake Louise criteria [41]. CMR is now 
recommended by European guidelines as first line imag-
ing technique, prior to endomyocardial biopsy, in stable 
patients with suspected myocarditis [42]. Some studies sug-
gest that myocarditis is a dynamic process which spreads 
from focal to disseminated myocardial involvement; CMR 
can timely follow-up this dynamic process [43]. The find-
ings of LGE ischemic distribution pattern on CMR allows 
the identification of patients with “true” MI despite unob-
structed coronaries on angiogram, such is the case of 
distal plaque embolization, coronary spasm or paradoxical 
embolization from a patent foramen ovale [38] (Fig. 3c, d). 
Tako-Tsubo cardiomyopathy, otherwise known as broken-
heart syndrome or stress cardiomyopathy, accounts for up 
to 0.7–2.5% of all ACS, up to 12% in the female population 
[16] (Fig. 3e, f). TTC frequently presents as ACS-STEMI 
with evidence of unobstructed coronaries; it typically 
shows peculiar regional wall motion abnormality, involving 
the mid-distal segments of the heart. TTC is a reversible 
cardiomyopathy, which usually resolves within 6 months 
from the acute event, and can be detected on ventricular 
cine-angiogram and on TTE, mainly based on the typical 
regional wall motion abnormality. CMR provides an added 
value based on tissue characterization, showing a transient 
myocardial injury, characterised by the presence of myo-
cardial oedema on T2-weighted images (Fig. 3e). Though 
it was once believed that in TTC LGE is absent, LGE has 
been found in a non-negligible proportion of cases, prob-
ably as a reflection of an underlying inflammatory response 
and transitory increase of extracellular space due to the 
myocardial oedema [44]. This is however reversible and no 
longer observed at follow-up in conjunction with the reso-
lution of myocardial oedema/inflammation. The diagnostic 
value of CMR in patients with acute chest pain has been 
tested in the Emergency Department in the assessment of 
stable patients with chest pain, non-diagnostic electrocar-
diogram (ECG) and increased cardiac enzymes; in a study 
on 161 stable patients with acute chest pain, CMR showed 
high sensitivity and specificity in detecting ACS, being 
more sensitive and specific than the ECG [45].
Chronic ischemic heart disease
Due to its ability to identify myocardial fibrosis, CMR 
has had its widest application in the assessment of chronic 
ischemic heart disease (IHD) [46, 47]. Detection of fibrosis 
is based on the analysis of the distribution of the contrast 
agent within the myocardium, 10–15 min after its admin-
istration. CMR uses gadolinium-chelate contrast agent, an 
extra-cellular agent, which is quickly washed out by nor-
mal myocardium, and accumulates in damaged myocar-
dium with expanded extra-cellular space [39]. Whether 
the extra-cellular space is expanded because of myocardial 
cell rupture in the setting of acute myocardial infarction 
or because of collagen deposition in the setting of chronic 
myocardial scarring, gadolinium will accumulate and be 
detected on CMR. Myocardial fibrosis can be present as 
infarct, replacement or diffuse fibrosis; these represent 
a continuum of myocardial damage, rather than isolated 
entities, as shown by Beltrami et  al. [48] who found that 
replacement and diffuse fibrosis account for 70% of all 
fibrotic tissue in end-stage IHD, while infarct fibrosis only 
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Fig. 3  Acute coronary syn-
dromes with normal angiogram. 
Early gadolinium enhancement 
sequences showing extensive 
epicardial enhancement (a, 
black arrow) and correspond-
ing late gadolinium (LGE) on 
the post-contrast sequences (b, 
black arrow) in a patient with 
acute myocarditis. T2-weighted 
images showing focal discrete 
oedema in the mid-cavity 
inferolateral wall (c, white 
arrow) with corresponding LGE 
on post-contrast sequences (d, 
white arrow) in a patient with 
embolic myocardial infarction 
in the mid left circumflex ter-
ritory. T2-weighted sequences 
showing acute myocardial 
oedema in the apical segments 
(e) with no evidence of late 
gadolinium enhancement (LGE) 
on the post-contrast sequences 
(f) in a patient with Tako-Tsubo 
cardiomyopathy
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accounts for 30%. The accuracy of CMR in assessing the 
ischemic scar has been validated in animal studies, which 
showed that the location, extent and shape of LGE on ex-
vivo CMR were almost identical to the infarcted areas 
defined on histologic analysis [49]. CMR’s excellent con-
trast and spatial resolution allow the identification of even 
small amounts of infarct scar, below 1 g of mass [50, 51]. 
CMR has shown to be superior to single photon emission 
tomography (SPECT) in the assessment of myocardial scar, 
especially in cases of small infarct and infarct in a non-
anterior location [52]. Infarct healing is a well-known pro-
cess, that can easily be detected and followed-up by CMR. 
A study on 58 reperfused STEMI patients showed that 
infarct size reduces 4 months after the acute event, but is 
relatively unchanged at 1 year follow-up [53]; in the acute 
phase infarct volume is influenced by hyperaemia, oedema 
and inflammation, which might explain the overestima-
tion of infarct size early after the acute event [54]. How-
ever, infarct size at baseline has proved to be the strongest 
predictor of adverse long-term LV remodelling [53], which 
continues for up to a year after the acute event, also involv-
ing the remote non-infarcted myocardium. There is a strong 
linear relation between scar size, LV end-systolic (LVESV) 
and end-diastolic volumes (LVEDV) and LVEF. Scar size 
is the strongest predictor of LVEF, independent of scar 
location and transmurality [55]. A study on 90 reperfused 
anterior STEMI undergoing CMR early (3–5 days) and 90 
days from the acute event showed that baseline infarct size, 
infarct heterogeneity and myocardial salvage are signifi-
cantly associated with 90-day LVEF [56].
Myocardial viability
Transient ischemia impairs LV function, acutely and 
chronically, if repeated episodes occur; acute ischemic LV 
impairment is known as myocardial stunning, while chronic 
ischemic impairment is known as myocardial hibernation 
[57]. However, ischemic LV dysfunction is not necessarily 
an irreversible process, and LV function can improve after 
revascularization [58]. Myocardial viability is a reflec-
tion of impaired ischemia-induced contractility at rest that 
recovers after revascularization. The assessment of myo-
cardial viability is the cornerstone to guide clinical treat-
ment, as it has been shown that complete revascularization 
of viable myocardium reduces long-term adverse events, 
as compared to medical therapy [59]. Myocardial viability 
was once defined on TTE and PET, by means of LV wall 
thickness, wall motion abnormality on low-dose dobu-
tamine echocardiography [57] and reduced metabolism. 
Low-dose dobutamine stress CMR has good specificity 
(83%) and moderate sensitivity (74%), not dissimilar from 
those of stress dobutamine echocardiography; a “bi-phasic 
response” is highly predictive of functional recovery [60]. 
The concept of myocardial viability was expanded by the 
implementation of scar analysis on CMR [61], which has 
shown better sensitivity, specificity and accuracy than 
SPECT in the prediction of myocardial viability [62]. 
Extent of LGE is significantly associated with myocardial 
viability and functional recovery. Kim et al. [63] assessed 
LGE extent and myocardial contractility before and after 
revascularization in 50 patients presenting with impaired 
LV systolic function, showing that improvement in LV con-
tractility decreases with the increase in scar transmurality: 
78% of LV dysfunctional segments with no LGE improved 
in function, compared to only 2% of those with evidence of 
>75% LGE. A study on patients undergoing CMR before, 
early (6 days) and late (6 months) after surgical revascu-
larization, showed that LGE transmurality strongly related 
to recovery in regional function at 6 months [64]. Using 
a 50% trasmural viability cut-off, 10 viable + normal seg-
ments predicted ≥3% improvement in LVEF, with a sensi-
tivity of 95% and specificity of 75% [65]. Different studies 
found that irreversibly damaged myocardium was charac-
terised by reduced wall thickness, so that reduced end-dias-
tolic wall thickness was predictive of no myocardial recov-
ery after revascularization [66]. Though regional LV wall 
thinning has been long thought to represent chronic trans-
mural scar, Shah et  al. [67] showed that among patients 
with CAD found to have LV wall thinning (≤5.5  mm at 
end-diastole) 18% had only a small scar burden (≤50% of 
total extent), which was associated with improved contrac-
tility and resolution of wall thinning after revasculariza-
tion (Fig. 4). The assessment of scar in IHD has important 
prognostic implications. First, it predicts late myocardial 
recovery soon after the acute ischemic event; LGE volume 
after acute STEMI proved to be the strongest predictor of 
late LV dysfunction, over and above infarct transmurality, 
MVO and myocardial salvage, with a hazard ratio of 6.1 for 
adverse events when LGE extent was ≥23% [68]. The asso-
ciation of greater infarct size and impaired LVEF predicts 
even poorer outcome [69]. Infarct size, LVEF and LVESV 
on CMR predict future cardiac events early (1 week) after 
acute STEMI [70]. Among patients with clinically sus-
pected CAD but with no history of MI, evidence of LGE on 
CMR is associated with worse outcome, and remains the 
strongest predictor of adverse events, even after adjustment 
for significant CAD on angiogram, LVEF and wall motion 
abnormality [71, 72].
Risk stratification
The assessment of infarct scar is important also to risk 
stratify patients according to their risk of arrhythmic 
events, as it is well known that myocardial scar represents 
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the substrate for re-entrant arrhythmias [73]. Different stud-
ies on patients undergoing CMR prior to ICD implantation 
have shown that scar extent is stronger than LVEF in pre-
dicting arrhythmic events (sudden death, ICD discharge, 
ventricular arrhythmias) and inducibility at electrophysi-
ologic study (EPS) [74–76] and remains the strongest pre-
dictor, also in patients with preserved ejection fraction [77]. 
Scar analysis on CMR is based on different signal inten-
sity of the infarcted area as compared to an area of normal, 
remote myocardium. Most studies have defined the cut-off 
for abnormal signal intensity at 5 SD above that of normal 
myocardium to identify the core infarct and between 2 and 
3 SD above normal myocardium to identify the peri-infarct 
zone, though the full width at half maximum technique has 
Fig. 4  Myocardial viability and 
left ventricular (LV) recovery 
after revascularization. Long-
axis two (a) and four chamber 
(b) cine sequences showing 
marked thinning of the LV 
anterior and anteroseptal walls 
in a patient with severe disease 
of the mid-distal left anterior 
descending (LAD); post-con-
trast sequences showing viable 
myocardium in the mid-distal 
LAD territory as late gado-
linium enhancement (LGE) is 
limited to the subendocardium 
(c, d, white arrow). Long-
axis two (e) and four chamber 
(f) cine sequences showing 
recovery of LV wall thickness 3 
months after revascularization 
of the LAD
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shown to be the most accurate and reproducible, regardless 
of the underlying myocardial disease [78]. Detailed semi-
automated scar analysis allowed the identification of an 
even higher association between the peri-infarct zone and 
the arrhythmic risk. It is now believed that tissue heteroge-
neity is the strongest predictor of EPS inducibility and free-
dom from recurrence after ventricular tachycardia ablation 
[79, 80]. CMR is thus a valuable tool also in the assessment 
of patients prior to ICD implantation, and there is recent 
evidence that scar extent on CMR predicts response to car-
diac resynchronization therapy (CRT) [81, 82]; in a study 
on 47 IHD patients undergoing CRT, CMR showed that 
response rate to CRT was higher in patients with higher 
LVEF, smaller scar and lower number of LV segments with 
>51% scar transmurality [82]. Finally, primary prevention 
ICD implantation is based on LVEF [83]. CMR is the gold 
standard for the assessment of LVEF as it is free from any 
geometric assumption [84, 85]: based on full 3D coverage 
of the heart, by contouring the endo- and epicardial bor-
ders, CMR provides 3D volumetric assessment of ventricu-
lar volumes and function.
Stress perfusion CMR
Stress CMR has been recently recognised as a reliable tech-
nique to diagnose myocardial ischemia in the setting of 
CAD. It is based on the assessment of myocardial perfu-
sion during pharmacological stress testing with coronary 
vasodilators (Fig. 5), and on the detection of inducible wall 
motion abnormalities during high-dose dobutamine infu-
sion (HDD-CMR). The most used vasodilator is adeno-
sine, mainly because of its short-life and limited side 
effects; adenosine increases coronary artery vasodilata-
tion in normal coronaries, but it does not increase blood 
flow downstream to stenotic arteries as the arteriolar bed 
is already maximally dilated (so-called “coronary steal” 
phenomenon); this allows the identification of areas of 
hypoperfused myocardium distal to a significant stenosis 
[86], which appear as a low signal intensity (dark) area on 
stress perfusion images (Fig. 5a–c). Stress perfusion CMR 
showed good diagnostic performances in several studies 
[87]. In a meta-analysis of 12 studies (761 patients) using 
fractional flow reserve (FFR) as a reference standard, per-
fusion CMR had a sensitivity of 89.1% and specificity of 
84.9% on a patient basis as well as a sensitivity of 87.7% 
and specificity of 88.6% on a coronary territory basis [88]. 
Nandalur et al. showed that perfusion CMR has a sensitiv-
ity of 91% and a specificity of 81% in a per-patient analysis, 
and of 84 and 85% respectively for the identification of the 
ischemic segments [89]. Recently, a large randomized trial 
has shown that perfusion CMR has better sensitivity and 
negative predictive values compared to SPECT, and that 
it offers an accurate assessment of single-vessel and multi-
vessel coronary disease, irrespective of the cut-off used for 
defining clinically significant coronary artery stenosis [90].
Perfusion CMR assessment of coronary flow reserve has 
also been compared with PET, and there was an excellent 
correlation between the two modalities [91]. Dobutamine 
is a sympatomimetic amine with positive inotropic and 
chronotropic effects, that mimics the physiological effect 
of physical exercising, inducing increased oxygen demand 
[86]. When administered at low-dose it usually determines 
the recruitment of the contractile reserve of hibernating 
myocardial segments (dysfunctional but viable myocardium 
at rest), but when given at high-dose it induces ischemia in 
territories with significant coronary artery stenosis, which 
is expressed as the onset of wall motion abnormalities, easy 
to recognize on CMR cine images. HDD-CMR has been 
shown to be superior to dobutamine stress echo (DSE) 
with significantly higher diagnostic accuracy, probably due 
to superior image quality allowing a better assessment of 
regional wall motion abnormalities [92]. However “the vis-
ual assessment-based” interpretation of wall motion abnor-
malities can lead to different results. Recently, the intro-
duction of the feature tracking software (FT), allowing the 
assessment of myocardial strain from cine images, without 
the need for additional sequences, has improved this limi-
tation. Schneeweis et al. showed that FT based analysis of 
circumferential strain during HDD-CMR was feasible and 
helped differentiating between normal myocardium and 
segments supplied by a stenotic coronary artery, suggesting 
that the quantitative assessment of myocardial strain with 
FT may improve the diagnostic accuracy of HDD-CMR for 
detection of ischemia [93].
Prognosis
Many studies have been published regarding the assess-
ment of prognosis with stress-CMR [94, 95]. Sozzi et al., 
showed that among 326 consecutive patients with normal 
adenosine stress perfusion CMR the event rate was low and 
prognosis excellent over a 5.5-year period [96]. Kelle et al. 
found that, in a large cohort of patients with negative dobu-
tamine stress, the annual cardiac event rate was 1.1% while 
the hazard ratio associated with a positive test was 3.3 [97]. 
In a large meta-analysis of 19 studies, involving a total of 
11,636 patients with a mean follow up of 32 months, Lipin-
ski et al. found that a negative stress CMR was associated 
with very low-risk of cardiovascular death and myocar-
dial infarction, suggesting that stress CMR may help in 
the risk stratification of patients with known or suspected 
CAD [98]. Based on those data, current clinical guidelines 
for myocardial revascularization, suggest the use of stress 
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CMR in the management of patients with intermediate risk 
of CAD and stable symptoms (class IA) [99].
The 5-year follow up of the CE-MARC study demon-
strated that compared to SPECT, CMR is the strongest 
predictor or risk for MACE, independent of cardiovas-
cular risk factors, angiographic result, or initial patient’s 
treatment [100].
Fig. 5  Stress perfusion CMR. Three slice (base, mid and apex—a, 
b and c, respectively) short axis stress perfusion sequences acquired 
at peak adenosine infusion showing two separate areas of hypoperfu-
sion, in the proximal to distal inferior (a–c, white arrow) and mid-
cavity anterior walls (b, white arrow), with a normal rest perfusion 
(d–f) and only a discrete area of subendocardial late gadolinium 
enhancement in the mid-cavity anterior wall (h) on post-contrast 
images (g–i). Overall, these findings are consistent with induci-
ble myocardial ischemia in all right coronary artery territory with 
ischemia superimposed to the infarcted area in the mid left anterior 
descending territory
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Indications of CMR in ischemic heart disease: 
international guidelines
According to international guidelines, CMR plays a role 
in the assessment of patients with ischemic heart disease. 
2013 ESC guidelines on stable angina recommended imag-
ing stress testing (IB) for risk stratification in patients with 
known stable CAD and a deterioration of symptoms as a 
guide to clinical decision making and in the assessment of 
patients with intermediate pre-test probability (15–85%) of 
CAD [101]. Imaging stress test was also recommended in 
symptomatic patients with prior myocardial revasculariza-
tion or to assess functional severity of intermediate lesions 
on angiography (IIaB). Stress testing with CMR is also 
recommended before or after discharge to assess residual 
myocardial ischemia and viability in STEMI patients (IA) 
[1]. More recently, stress CMR has been given a class IA 
indication by the new European Society of Cardiology 
guidelines on myocardial revascularization [99] to assess 
suspected CAD in patients with intermediate pre-test 
probability.
Limitations
Though CMR is increasingly used, its availability is still 
limited in certain centres. CMR can definitely be per-
formed safely also in the acute setting, but the patient needs 
to be haemodinamically stable. There are few contraindi-
cations to CMR. Patients with non-MR conditional devices 
(intracranial clips, neuro-stimulator, metallic objects in 
the eye) should not be offered a CMR; recent advances 
in technology do provide MR-conditional cardiac devices 
(pace-maker and ICD), that allow CMR scanning, though 
under strict medical monitoring. Gadolinium-chelate con-
trast agent is safer than iodine contrast agents, but should 
be avoided in severe renal dysfunction (eGFR < 30  ml/
min/1.73 m2), as it increases the risk of nephrogenic sys-
temic fibrosis, a potentially fatal condition. Claustrophobia 
has long been thought to be an absolute contraindication 
to CMR; however, performing CMR with the patient lying 
prone, providing an angulated mirror in the CMR bore to 
allow the patients to look outside the scanner and inviting a 
relative to sit at the end of scanner should help reduce these 
cases to a negligible percentage.
Conclusion
CMR is a well-established imaging tool, which allows 
a comprehensive, multi-parametric cardiac assessment 
in a 40-min one-stop-shop technique. The use of CMR 
in ischemic heart disease has rapidly spread given its 
superior diagnostic properties and important prognostic 
implications.
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